Gilead Sciences GILD Trodelvy — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's trodelvy — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's trodelvy — total revenues?
- Gilead Sciences (GILD) reported trodelvy — total revenues of $402M in Q1 2026.
- How has Gilead Sciences's trodelvy — total revenues changed year-over-year?
- Gilead Sciences's trodelvy — total revenues increased by 37.2% year-over-year, from $293M to $402M.
- What is the long-term trend for Gilead Sciences's trodelvy — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's trodelvy — total revenues has grown at a 38.5% compound annual growth rate (CAGR), from $380M to $1.4B.
- What does trodelvy — total revenues mean?
- The total amount of money earned from sales of the Trodelvy drug product line.
- How do you interpret trodelvy — total revenues?
- An increase indicates growing market penetration, successful expansion into new patient populations, or effective commercial execution for this specific therapy. A decrease may signal increased competition, loss of market share, or challenges in clinical adoption.
- How does trodelvy — total revenues compare across companies?
- Comparable to oncology product revenue lines at other biopharmaceutical companies, often benchmarked against the growth rates of competing targeted therapies in the breast cancer or solid tumor markets.